Zacks small cap research.

John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

Zacks small cap research. Things To Know About Zacks small cap research.

Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …Sep 2, 2022 · Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release (ER) capsules. These results combined with the data released in June show that both ... By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported third quarter results on November 14, 2022 in a press release and in its Form 10-Q filing. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing …By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ...

19 May 2013 ... Zacks is a hoax. Top rated stocks become low rated stock very quickly. Out of approximately 20 top pick I had two that made money and all ...May 22, 2023 · By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ... Zacks Small Cap Research. TENX: Notice of Allowance Increases Confidence. Read full article. Zacks Small Cap Research. June 23, 2023 at 3:24 AM ...

Nov 27, 2023 · On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) were presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) ( Lauko et al., 2023 ). The Phase 2 clinical trial enrolled 62 GBM patients (36 newly diagnosed and 26 ...

A bad radiator cap can cause the coolant to boil over from the reservoir or the engine to overheat. The cap is an integral piece of an engine’s cooling system as it retains the coolant´s pressure.Sep 2, 2022 · Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release (ER) capsules. These results combined with the data released in June show that both ... In a March 28, 2023 press release, Allarity announced updates to its Phase II programs that are evaluating Ixempra and stenoparib as monotherapies. The pace of recruitment for both trials has been slow due to impacts from the pandemic and from on-site personnel staffing. To address the issue, Allarity has engaged additional contract research ...In the financial sphere, Protalix generated revenues of $6.4 million in 2Q:21 compared to revenue of $11.0 million in the prior year period. This resulted in net loss of ($11.2) million versus loss of ($4.2) million in 2Q:20. Financial results for the quarter ending June 30, 2021 compared to the quarter ending June 30, 2020:SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Sep 14, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. _____ 1. BioLineRx Corporate Website, Accessed September 2023.

Working with Lumentum, POET’s optical engines will be the industry’s first implementation of DMLs at these rates. Its small size and chip-on-board design will allow 800G and 1.6T designs to easily fit in an industry-standard 1.6T OSFP-XD form factor. The 400G FR4 optical engines will use the industry’s first flip-chip integration on an ...

Mar 23, 2023 · By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include Nov 27, 2023 · 06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023. DIREXION DAILY SMALL CAP BULL 3X SHARES. The Direxion Daily Small Cap Bull 3x Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index ...ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other serious illnesses.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Apr 10, 2023 · RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.

Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ... Financial Results. In its latest fiscal quarter ending December 31 st, IBS generated total revenues of $626,000 compared to $178,000 in the prior year period. 2Q:23 revenues included a component from both Intelligent Fingerprinting (IFP) and government support revenue while 2Q:22 revenues only included the government support component ...Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA. By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...The TSP-21-G form is the loan agreement form individuals sign when they borrow against their Thrift Savings Plan accounts, according to the U.S. Government Publishing Office. TSP loans are only available to current military and federal empl...By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ: ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information …

May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ...

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remainedBy Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remainedNov 15, 2023 · SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the ... Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.Forgot your password? Email us at [email protected] for assistance ...Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of ResearchINX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...The Morningstar US Small Cap Extended Index comprises of small-capitalization U.S. equities. The ETF return is roughly 10.19% so far this year and is up …

Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believe

Ann H. Heffron, CFA, CPA is a Senior Analyst at Zacks Investment Research. Ann has over 25 years of investment research experience, primarily working as a securities analyst following banks and other financial institutions for a number of firms in the Chicago area. ... Prior to joining Zacks, Ann was a Senior Vice President at Zurich Scudder ...

Frequent use can lead to cannabis use disorder, characterized by withdrawal symptoms, cravings, and difficulty quitting, which can have a significant impact on one's daily life. Additionally, smoking or vaping THC can harm lung health and may increase the risk of respiratory issues. Furthermore, THC can impair motor coordination and judgment ...Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising …By Lisa Thompson NASDAQ:GROM Fresh off a December $5.0 million capital raise and reverse split in December, Grom Social Enterprises (NASDAQ:GROM) is poised to capitalize on a number of promising initiatives over the next several months. The company now has 3.2 million in fully diluted shares and trades at a market capitalization …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Equity Research December 04, 2023. Better trading ... Ahead of today’s normal trading session, only the small-cap Russell 2000 is in the green at this …Update on Phase 1 Trial of EPI-7386. ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy ( NCT04421222 ).Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.78 to $16.84 per …John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

Nov 10, 2023 · LGVN Continues to Show Progress. Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of ... Zacks Investment Research Page 4 scr.zacks.com The company has already presold the bulk of its 2023 capacity (and likely a significant portion of 2024 capacity) to customers and continues to announce customer wins with industry leaders in the energy storage market.Mar 23, 2023 · By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...Instagram:https://instagram. dynatronics corporationhershey stocksbest gold and silver etfwhat are the quarters that are worth money SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting … trustmark stockthe merge nft We estimate the company has sufficient capital to fund operations into the third quarter of 2023. On November 22, 2022, Qualigen announced a 1-for-10 reverse stock split, thus we estimate that the company currently has approximately 4.2 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count …OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ... mbs spreads Free Weekly Digest Zacks Small Cap Research covers more than 100 small- and micro-cap companies that are under-followed or under-valued by Wall Street. Our analysts cover all major sectors... Zacks Small Cap Research. BBLG: BBLG Has Solid Cash and Is Advancing Testing. Read full article. Zacks Small Cap Research. May 16, 2023 at 7:20 AM ...When it comes to fastening two objects together, cap head bolts and cap head screws are two popular options. They both have a similar appearance, but they differ in their application and usage. In this article, we’ll explore the difference ...